The Maryland Proton Treatment Center is offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.
Yale researchers have identified factors that may contribute to widening cancer death disparities among counties across the United States. These factors, which include both socioeconomic and behavioral traits, may provide public health experts with specific targets for potentially reducing cancer disparities, the researchers said.
The highest priority in a national cancer control plan must be expansion of tobacco control—the intervention with the largest potential health benefits—according to a new American Cancer Society report, the second in a series of articles that together inform priorities for a comprehensive cancer control plan.
Regular use of aspirin can reduce the risk of developing ovarian cancer and hepatocellular carcinoma, according to two studies published Oct. 4 in JAMA Oncology.
Genentech announced the results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA trials, which showed that entrectinib shrank tumors (objective response rate) in 77.4 percent of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Findings from the NELSON study demonstrate that the use of computed tomography screening among asymptomatic men at high risk for lung cancer led to a 26 percent (9-41%, 95% CI) reduction in lung cancer deaths at 10 years of study follow-up (at 86% compliance).
Imfinzi (durvalumab) reduced the risk of death by nearly one-third compared to placebo in the phase III PACIFIC trial.
Genentech announced positive results from the phase III IMpower133 study of Tecentriq (atezolizumab) plus carboplatin and etoposide for the initial treatment of people with previously-untreated extensive-stage small cell lung cancer.
Findings from a recent study demonstrate that the use of atezolizumab, a PD-L1 inhibitor, in combination with carboplatin plus pemetrexed as first-line therapy and pemetrexed as maintenance therapy improves progression free survival in patients with stage IV non-squamous non-small cell lung cancer.
Myriad Genetics announced that results from a landmark study of variant classifications following hereditary cancer genetic testing were published in the Journal of the American Medical Association.
